Multistate Outbreak of Burkholderia cepacia Infections | Outbreak Resources | HAI | CDC

Multistate Outbreak of Burkholderia cepacia Infections | Outbreak Resources | HAI | CDC

The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.

FDA continues to work with CDC to find the source or sources of the Burkholderia cepacia outbreak and will provide additional information when it is available. At this time, there is no epidemiologic or laboratory evidence to suggest oral capsules or enemas are affected. Most importantly, we join CDC in recommending that facilities not use any oral liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Additionally, facilities that experience B. cepacia complex infections among non-cystic fibrosis patients or clusters of B. cepacia complex infections among cystic fibrosis patients should sequester all oral liquid docusate products.

For more information, please visit: Burkholderia cepacia Infections.

Multistate Outbreak of Burkholderia cepacia Infections

Update June 29, 2016

Preliminary information continues to indicate that contaminated oral ‎liquid docusate products might be related to B. cepacia complex infections in one state. At this time, there is no epidemiologic or laboratory evidence to suggest oral capsules or enemas are affected. Until more information is available, CDC continues to recommend that facilities not use any oral liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Facilities that experience B. cepaciacomplex infections among non-cystic fibrosis patients or clusters of B. cepacia complex infections among cystic fibrosis patients should sequester all oral liquid docusate products.‎‎

Healthcare providers and laboratories should remain on alert for B. cepacia complex infections occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur.  In addition, clusters of B. cepacia complex infections among patients with CF should be reported when infection rates appear above endemic rates. Cases should be reported to state or local public health authorities. 

CDC will provide an update to this announcement by July 7. Please direct questions to CDC athaioutbreak@cdc.gov.

Update June 24, 2016

The Centers for Disease Control and Prevention (CDC) is collaborating with the Food and Drug Administration (FDA), multiple state and local health departments, and numerous healthcare facilities to investigate a multi-state outbreak of Burkholderia cepacia infections. These infections have occurred primarily in ventilated patients without cystic fibrosis and who are being treated in intensive care units. 

Preliminary information indicates that a contaminated liquid docusate product might be related to cases in one state.  Until more information is available, CDC recommends that facilities not use any liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Institutions with non-cystic fibrosis patients in whom there are B. cepacia infections should sequester all liquid docusate products.

Healthcare providers and laboratories should be on alert for B. cepacia cases occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur. Cases should be reported to state or local public health authorities. 

Please direct questions to CDC at haioutbreak@cdc.gov.